Skip to content
Therapy But Better – Lifestyle
Author:
X4 Pharmaceuticals
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
April 29, 2026
←
Previous Page
1
2